HUB Organoids® in immuno-oncology drug development
Immunotherapies have shown substantial success as a treatment strategy to combat cancer. However, their efficacy is limited to only a subset of patients. Treatment failure can be attributed to the lack of predictive biomarkers of response and to the limited translatability from current preclinical models which fail to recapitulate the interaction between human tumors and the immune system, are prone to losing tumor-specific antigens, and are often suboptimal for large-scale studies.
This Info Sheet explores how to validate your immunotherapeutic using a patient-relevant platform.
This content was provided by HUB Organoids.
